BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8833216)

  • 1. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of different doses of nasal salmon calcitonin on bone mass.
    Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
    Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.
    Overgaard K; Christiansen C
    Calcif Tissue Int; 1996 Jul; 59(1):12-6. PubMed ID: 8661977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
    Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
    Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R; Sigaud A; Azria M; Herrmann FR
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
    Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
    Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
    Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
    Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.